Apraclonidine Hydrochloride and Zavesca

• Generic Name: apraclonidine ophthalmic
• Dosage Forms: n.a.
• Other Brand Names: Iopidine

Apraclonidine 1% is used prophylactically to prevent or reduce intraoperative and postoperative increases in intraocular pressure (IOP) before and after ocular laser surgery (e.g., argon laser trabeculoplasty, argon laser iridotomy, neodymium yttrium aluminum garnet [Nd:YAG] laser posterior capsulotomy).

Apraclonidine 0.5% is used for short-term (<1 month) adjunctive therapy in patients with open-angle glaucoma receiving maximally tolerated drug therapy (i.e., a topical β-adrenergic blocking agent in conjunction with a systemically administered carbonic anhydrase inhibitor and a sympathomimetic and/or a parasympathomimetic agent) who require additional reduction in IOP.

• Generic Name: miglustat
• Dosage Forms: capsule
• Other Brand Names: Zavesca

Zavesca (miglustat) reduces the formation of a certain protein in the body in people with type 1 Gaucher disease.

Gaucher disease is a genetic condition in which the body lacks the enzyme needed to break down certain fatty materials (lipids). Lipids can build up in the body, causing symptoms such as easy bruising or bleeding, weakness, anemia, bone or joint pain, enlarged liver or spleen, or weakened bones that are easily fractured.

Zavesca is used to treat mild to moderate type 1 Gaucher disease by people who cannot receive enzyme replacement therapy.

Zavesca may improve the condition of the liver, spleen, bones, and blood cells in people with Type I Gaucher disease. However, it is not a cure for this condition.

Zavesca may also be used for purposes not listed in this medication guide.